These innovative molecules represent a significant leap in the management of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates promising efficacy in controlling blood glucose levels. https://geraldbxor516981.imblogs.net/88735945/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide